• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Other Events

    6/16/25 4:25:47 PM ET
    $LIPO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LIPO alert in real time by email
    false 0001347242 0001347242 2025-06-16 2025-06-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): June 16, 2025

     

    Lipella Pharmaceuticals Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   005-93847   20-2388040
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)   (IRS Employer
    Identification No.)

     

    7800 Susquehanna St., Suite 505

    Pittsburgh, PA

      15208
    (Address of registrant’s principal executive office)   (Zip code)

     

    Registrant’s telephone number, including area code: (412) 894-1853 

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

      ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

      ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
         
      ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
         
      ☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which
    registered
    Common Stock, par value $0.0001 per share   LIPO   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

      

     

     

    Item 8.01 Other Events

     

    Lipella Pharmaceuticals Inc. (the “Company”) intends to hold its 2025 annual meeting of stockholders (the “2025 Annual Meeting”) on July 21, 2025. The Company has set the close of business on June 18, 2025 as the record date for the determination of stockholders who are entitled to notice of, and to vote at, the 2025 Annual Meeting and any adjournments thereof. The time and location of the 2025 Annual Meeting will be specified in the Company’s definitive proxy statement on Schedule 14A for the 2025 Annual Meeting.

     

    The Company’s 2024 annual meeting of stockholders (the “2024 Annual Meeting”) was held on September 10, 2024. As the date of the 2025 Annual Meeting will have been changed by more than 30 days from the one-year anniversary of the 2024 Annual Meeting, the Company is informing stockholders of this change in accordance with Rule 14a-5(f) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is informing stockholders of the new dates described below for submitting stockholder proposals and other matters.

     

    Pursuant to Rule 14a-8 of the Exchange Act, a stockholder intending to present a proposal to be included in the proxy statement for the 2025 Annual Meeting must deliver the proposal in writing to the Company’s Secretary at its corporate office at 7800 Susquehanna St., Suite 505, Pittsburgh, PA 15208 no later than a reasonable time before we begin to print and mail the proxy materials for the 2025 Annual Meeting. To be considered for inclusion in this year’s proxy materials for the 2025 Annual Meeting, shareholder proposals must be submitted in writing on or before the close of business on June 18, 2025, which the Company believes to be a reasonable deadline under the applicable rules of the Exchange Act. In addition to complying with such deadline, stockholder proposals intended to be considered for inclusion in the Company’s proxy materials for the 2025 Annual Meeting must also comply with Delaware law, the Company’s second amended and restated by-laws, as well as all applicable rules and regulations promulgated by the U.S. Securities and Exchange Commission under the Exchange Act. Any director nominations and stockholder proposals received after such deadline will be considered untimely and will not be considered for inclusion in the proxy materials for the Annual Meeting nor will it be considered at the Annual Meeting.

     

    In addition, any stockholder who wishes to make a nomination or introduce an item of business at the 2025 Annual Meeting, other than pursuant to Rule 14a-8 under the Exchange Act, must deliver proper notice to us in writing to our Corporate Secretary at our corporate office at 7800 Susquehanna St., Suite 505, Pittsburgh, PA 15208 not later than the close of business on June 20, 2025.

     

    In addition, to comply with the SEC’s universal proxy rules, stockholders who intend to solicit proxies in support of director nominees other than the Company’s nominees must provide notice in writing to our Corporate Secretary at our corporate office at 7800 Susquehanna St., Suite 505, Pittsburgh, PA 15208 setting forth the information required by Rule 14a-19 under the Exchange Act no later than the close of business on June 20, 2025.

     

      

     

      

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: June 16, 2025 Lipella Pharmaceuticals Inc.  
           
      By: /s/ Jonathan Kaufman  
       

    Name: Jonathan Kaufman

    Title: Chief Executive Officer

     

     

     

     

      

     

     

    Get the next $LIPO alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $LIPO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $LIPO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Kaufman Jonathan H bought $7,590 worth of shares (10,000 units at $0.76), increasing direct ownership by 1% to 898,849 units (SEC Form 4)

      4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)

      5/15/24 4:39:19 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kaufman Jonathan H bought $45,452 worth of shares (55,000 units at $0.83), increasing direct ownership by 7% to 888,849 units (SEC Form 4)

      4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)

      3/19/24 6:21:08 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LIPO
    SEC Filings

    See more
    • Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)

      6/25/25 3:14:40 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)

      6/20/25 4:02:53 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Other Events

      8-K - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)

      6/16/25 4:25:47 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LIPO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Lipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting

      PITTSBURGH, June 25, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (OTC:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet need, today issued a letter from Chief Executive Officer Jonathan Kaufman to stockholders. The letter provides detailed responses to frequently asked questions regarding the Company's recent delisting from the Nasdaq Capital Market, as well as insight into Lipella's clinical programs, financial position, and plans to relist on a national exchange. In the letter, Dr. Kaufman acknowledged the many inquiries received from stockholders and reaffirmed the Company's commitmen

      6/25/25 3:15:00 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market

      PITTSBURGH, June 20, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (OTC:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet needs, today announced that the Nasdaq Hearings Panel has determined to delist the Company's common stock from The Nasdaq Capital Market. Trading in the common stock was suspended at the open of business today. The delisting follows Nasdaq's determination that certain private placement transactions completed between December 2024 and March 2025 did not comply with Listing Rules 5100 (Public Interest Concern), 5635 (Shareholder Approval), and 5640 (Voting Rights). Spec

      6/20/25 3:19:25 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lipella Pharmaceuticals Announces U.S. Patent Issuance for Diagnostic Technology

      PITTSBURGH, June 17, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet need, today announced the issuance of U.S. Patent No. 12,326,492, titled "Systems and Methods of Detecting Interstitial Cystitis." The patent was issued by the United States Patent and Trademark Office on June 10, 2025, and provides protection through at least 2045, subject to potential extensions. The patent covers a method, using magnetic resonance imaging (MRI), to detect lesions (or permeability defects) in body cavities. "This method can potentially provide enha

      6/17/25 8:30:00 AM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LIPO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Officer Kaufman Jonathan H

      4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)

      4/7/25 7:16:11 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Officer Kaufman Jonathan H

      4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)

      3/17/25 8:12:52 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Officer Kaufman Jonathan H

      4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)

      3/11/25 8:01:27 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LIPO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Lipella Pharmaceuticals Inc.

      SC 13G/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)

      11/14/24 5:09:22 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Lipella Pharmaceuticals Inc.

      SC 13G/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)

      11/14/24 5:00:15 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Lipella Pharmaceuticals Inc.

      SC 13D/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)

      10/17/24 5:00:44 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care